General Information of the Compound
| Compound ID |
CP0066121
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine
Show/Hide
|
||||||||||||||||||
| Synonyms |
2-(Phenyl-o-tolylmethoxy)ethyldimethylamine
2-Methyldiphenhydramine
Antiflex
Banflex (TN)
Beta-Dimethylaminoethyl 2-methylbenzhydryl ether
Beta-Dimethylaminoethyl-2-methylbenzhydryl ether
Biorphen
Biorphen (TN)
Brocadisipal
Brocasipal
Brocasipal (TN)
Disipal
Disipal (TN)
Flexon (TN)
Lysantin
Mefenamine
Mephenamin (TN)
Mephenamine
Methyldiphenylhydramine
Mialgin (TN)
Myolin
Myotrol
N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin
N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine
N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine
N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine
N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine
N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine
N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine
Norflex (TN)
Norflex Orphenadrine Citrate
O-Methyldiphenhydramine
O-Monomethyldiphenhydramine
ORP
Orfenadrina
Orfenadrina [INN-Spanish]
Orfro
Orphenadine
Orphenadinum
Orphenadrin
Orphenadrine
Orphenadrine [INN:BAN]
Orphenadrine(INN)
Orphenadrinum
Orphenadrinum [INN-Latin]
Orphenate
Orphenedrine
Phenyl-o-tolylmethyl dimethyaminoethyl ether
Sodium Mefenamine
WS 2434
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C18H23NO
|
||||||||||||||||||
| Molecular Weight |
269.388
|
||||||||||||||||||
| Canonical SMILES |
CN(C)CCOC(c1ccccc1)c1ccccc1C
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3
Show/Hide
|
||||||||||||||||||
| InChIKey |
QVYRGXJJSLMXQH-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
83-98-7
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00817, Cytochrome P450 2D6
Protein ID: PT01206, Histamine H1 receptor
Protein ID: PT05367, Multidrug and toxin extrusion protein 1
Protein ID: PT05330, Multidrug and toxin extrusion protein 2
Protein ID: PT03795, Solute carrier family 22 member 1
Protein ID: PT04591, Solute carrier family 22 member 2
Clinical Information about the Compound